The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.Yuflyma (adalimumab-aaty, Celltrion USA) is a high-concentration (100 mg/mL), citrate-free biosimilar to the world’s top-selling Humira (adalimumab, AbbVie),
CorMedix Inc. (NASDAQ:NASDAQ:CRMD) Q1 2022 Earnings Conference Call May 12, 2022 16:30 ET Company Participants Daniel Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt.